Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that primary care physicians (PCPs) and managed care pharmacy directors agree that Viagra will remain the top seller in the erectile dysfunction drug market. While Cialis and Levitra both have improved attributes that make them attractive to physicians and patients, they will not be able to overtake Viagra's position in the market, according to a new primary research report from Decision Resources.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

The PhysicianForum report entitled Prospects for New Treatments for Erectile Dysfunction is composed of findings from a survey of PCPs and managed care pharmacy directors.

"Although Viagra will remain the first-line therapy of choice for erectile dysfunction, PCPs are ready to begin prescribing new phosphodiesterase (PDE) inhibitors, such as Cialis and Levitra, within three months of their launch in the United States," said Kat Neumeyer, analyst, Decision Resources. "However, health management organizations (HMOs) predict that Cialis and Levitra would not be added to formularies for up to six months, if at all."

PCPs said that cost was the most-cited reason for patients' discontinuation or refusal of Viagra therapy. A key decision for the manufacturers of both Cialis and Levitra is the price of the new PDE inhibitors; both HMOs and patients would welcome a lower price compared with Viagra.

"Sixty-seven percent of pharmacy directors reported they would add one of the new agents to their formularies if it was priced 40% below Viagra, and nearly 50% of pharmacy directors would add one if it was priced 30% below Viagra," continued Ms. Neumeyer.

Prospects for New Treatments for Erectile Dysfunction is based on a survey of 21 HMO pharmacy directors and 75 PCPs within the United States. Their responses were compared to assess similarities and differences in clinical, economic, and scientific factors.

About PhysicianForum

PhysicianForum is a new primary research service from Decision Resources. The service offers access to high-volume prescribing PCPs, specialists, and managed care organization representatives in the United States and Europe; analysis of events and survey participants' responses to them; insight into prescribing patterns; and implications for the pharmaceutical market.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563    emarshall@dresources.com 

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall for Decision Resources, +1-781-296-2563,
emarshall@dresources.com

Following Disappointing Phase III Clinical Trial Results, a Number of Novel Therapies for the Anithypertensive Market are Shelved

View Now